🔍

MOREPENLAB - Morepen Labs.

📊 NSE: MOREPENLAB 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:59

📢 Recent Corporate Announcements

Morepen Laboratories Repays ₹99 Crore Credit Facility to Kotak Mahindra Bank

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 11 Mar 2026, 05:00 PM

Morepen Laboratories has successfully repaid its entire credit facility totaling ₹99 crore to Kotak Mahindra Bank. The facility consisted of a ₹79 crore working capital demand loan and a ₹20 crore cash credit limit. The repayment was effective as of March 2, 2026, and the bank is now in the process of releasing the assets previously held as security. This move signifies improved liquidity and a commitment to deleveraging the balance sheet.

Full repayment of ₹99 crore credit facility to Kotak Mahindra Bank completed
Facility included ₹79 crore working capital demand loan and ₹20 crore cash credit
Repayment effective from March 2, 2026, with No Dues Certificate in process
Release of charged assets will improve the company's financial flexibility

💡 This is a positive development indicating strong internal accruals and debt reduction. Investors should look for a reduction in interest expenses in the upcoming quarterly financial statements.

Morepen Labs Secures ₹30 Crore Unsecured Working Capital Loan from KEB Hana Bank

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 10 Mar 2026, 07:01 PM

Morepen Laboratories has entered into an agreement with KEB Hana Bank to avail an unsecured working capital term loan of ₹30 crore. The loan carries a competitive interest rate of 7.30% per annum (Repo + 2.05%) and has a tenure of 3 years, including a 6-month moratorium. This facility is backed by a personal guarantee from the Promoter and CMD, Mr. Sushil Suri. The company's existing debt, excluding this new facility, stands at ₹164.62 crore.

Execution of a ₹30 crore unsecured working capital term loan facility with KEB Hana Bank.
Interest rate set at prevailing repo rate + 2.05%, currently effective at 7.30% per annum.
Loan tenure of 3 years with a 6-month moratorium and 5 half-yearly equal installments.
Personal guarantee provided by Promoter, Chairman & Managing Director Mr. Sushil Suri.
Total outstanding debt of the company (excluding this loan) is ₹164.62 crore as of March 10, 2026.

💡 Investors should monitor the company's debt-to-equity ratio and ensure that the additional working capital effectively supports revenue growth. The promoter's personal guarantee is a positive sign of internal confidence in the company's repayment capacity.

Morepen Labs Bags ₹825 Crore Global CDMO Order from International Pharma Major

🟢 POSITIVE ⭐ 9/10

EXPANSION 📅 23 Feb 2026, 05:42 PM

Morepen Laboratories has secured a significant international commercial supply contract worth approximately ₹825 crore (USD 91 million) from a leading global pharmaceutical company. This deal marks a major strategic expansion into the high-growth CDMO segment, with supplies expected to commence within the next 4-5 months. The contract is scheduled for execution over a 12-15 month period, concluding by Q1 of the following fiscal year. This order represents a substantial revenue opportunity and a shift towards higher-margin manufacturing services.

Secured a ₹825 crore (USD 91 million) international CDMO contract from a global pharma major
Execution timeline set for 12-15 months with supplies starting in 4-5 months
Strategic entry into the high-margin Contract Development and Manufacturing Organization (CDMO) segment
Contract includes both development and manufacturing services for the international market

💡 Investors should view this as a major growth catalyst that significantly improves revenue visibility and potential margins. Monitor the commencement of supplies in the next two quarters to ensure execution remains on track.

Morepen Labs Board Approves Rs 50 Crore Unsecured Term Loan from Woori Bank

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 11 Feb 2026, 03:08 PM

The Finance Committee of Morepen Laboratories has approved a proposal to avail an unsecured term loan facility of Rs 50 crore from Woori Bank. This capital infusion is intended to support the company's financial requirements, though specific end-use details were not disclosed in the initial filing. The loan is notable for being unsecured, meaning no company assets are pledged as collateral for this specific facility. Investors should await further disclosures regarding interest rates and repayment schedules once the formal loan documents are executed.

Approved an unsecured term loan facility aggregating to Rs 50 crore
Facility to be provided by Woori Bank
Approval granted by the Finance Committee of the Board on February 11, 2026
Loan agreement and related documentation to be executed in due course

💡 Investors should monitor the company's upcoming disclosures for the interest rate on this loan and how the funds will be deployed to ensure it generates a return higher than the cost of debt.

Morepen Labs Q3 FY26: Consolidated PAT Jumps 83% QoQ to ₹28 Cr; Medical Devices Up 44% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 03:26 PM

Morepen Laboratories reported a strong Q3 FY26 with consolidated revenue reaching ₹488 crore, a 17% growth over the previous quarter. The Medical Devices segment emerged as the primary growth engine, surging 44% YoY to ₹177 crore, driven by high demand for glucometers and BP monitors. While the Pharma business remained relatively flat at ₹285 crore, significant operational efficiencies led to a consolidated EBITDA growth of 42% QoQ. The company continues to strengthen its leadership in the home diagnostics market with a cumulative base of 16.85 million glucometers sold.

Consolidated PAT surged 83% QoQ to ₹28 crore, while EBITDA grew 42% QoQ to ₹50 crore.
Medical Devices revenue grew 44% YoY to ₹177 crore, now contributing 38% of the total business mix.
Glucometer revenue increased 40% YoY to ₹134 crore, supported by a massive base of 2.33 billion test strips sold.
Standalone gross revenue for Q3 FY26 stood at ₹462 crore, marking a 13% YoY increase.
API business remains the largest segment (62% share) with Atorvastatin leading the product mix at 26%.

💡 Investors should monitor the continued scaling of the high-growth Medical Devices segment, which is successfully diversifying the company's revenue away from pure APIs. The sharp improvement in quarterly margins and net profit suggests a positive trend in operational leverage.

Morepen Labs Q3 FY26 Results: Revenue Up 7% Y-o-Y to ₹484 Cr, Net Profit at ₹27.5 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 02:14 PM

Morepen Laboratories reported a steady performance for Q3 FY26, with consolidated revenue from operations growing 6.9% year-on-year to ₹484.16 crore. The consolidated net profit for the quarter stood at ₹27.51 crore, a marginal increase from ₹26.69 crore in the previous year's corresponding quarter. Operating performance showed strength as Profit Before Tax (before exceptional items) rose by 15.2% Y-o-Y to ₹31.69 crore. Investors should note that Dr. Morepen Limited ceased to be a subsidiary on July 31, 2025, which impacts the year-to-date consolidated comparisons.

Consolidated Revenue from operations increased to ₹484.16 crore in Q3 FY26 from ₹452.78 crore in Q3 FY25.
Profit Before Tax (before exceptional items) grew 15.2% Y-o-Y to ₹31.69 crore.
Net Profit for the quarter reached ₹27.51 crore compared to ₹26.69 crore in the same period last year.
Total Income for the nine-month period ended Dec 2025 stood at ₹1,333.82 crore.
Divestment of Dr. Morepen Limited (stake reduced to 19.96%) completed during the fiscal year, shifting it to an investment status.

💡 The steady growth in core operating profit despite the divestment of the consumer health subsidiary suggests improved focus on the pharmaceutical segment. Investors should monitor the company's margin expansion in the upcoming quarters as the new corporate structure stabilizes.

Morepen Labs Reports Status of Physical Share Transfer Requests Under SEBI Special Window

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Jan 2026, 06:08 PM

Morepen Laboratories has submitted a status report concerning physical share transfer requests for the period between January 1 and January 6, 2026. This disclosure follows a SEBI circular that established a special six-month window for re-lodging such requests. The report indicates that only one request was received during this period, which was ultimately rejected. No shares were successfully transferred or processed during this specific timeframe.

One request for physical share transfer received between Jan 1 and Jan 6, 2026
Zero requests were approved or processed during the reported period
The single request received was rejected by the RTA, MAS Services Limited
Compliance filing under SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97

💡 This is a routine administrative filing with no impact on the company's fundamentals. No action is required for investors holding shares in demat form.

Morepen Labs Reports Status of Physical Share Transfer Requests for December 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 07:26 PM

Morepen Laboratories has filed a status report regarding physical share transfer requests for the month of December 2025. This filing is in compliance with a SEBI circular that provided a special six-month window for shareholders to re-lodge transfer requests for physical shares. During the reporting period, the company received only one such request. This request is currently under process by the Registrar and Share Transfer Agent, MAS Services Limited.

Report submitted in accordance with SEBI circular dated July 2, 2025, regarding a special window for physical shares.
Only 01 request for re-lodgement of physical share transfer was received during December 2025.
Zero requests were approved or rejected during the month as the single request remains under process.
The status report was provided by the company's Registrar and Share Transfer Agent, MAS Services Limited.

💡 No action is required for investors holding shares in dematerialized form. This is a routine regulatory compliance update regarding legacy physical share certificates.

Morepen Labs Obtains High Court Stay on ₹117.94 Crore GST Show Cause Notice

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 08 Jan 2026, 07:18 PM

Morepen Laboratories has received a favorable interim order from the Himachal Pradesh High Court, which has stayed a Show Cause Notice (SCN) issued by the GST department. The SCN, dated December 2, 2025, alleged that the company erroneously claimed GST refunds totaling ₹117.94 crore. By obtaining this stay, the company has successfully halted the immediate operation of the tax demand. While the legal matter remains pending, the stay prevents any immediate financial outflow or operational disruption related to this specific tax claim.

Himachal Pradesh High Court granted a stay on the operation of a GST Show Cause Notice dated December 2, 2025.
The tax authority had alleged an erroneous GST refund claim amounting to ₹117,94,03,452.
The company challenged the notice through a writ petition, resulting in the court order dated January 6, 2026.
Management confirms there is currently no impact on financials or operations due to the grant of the stay.
The dispute pertains to Section 54 of the CGST Act and Rule 89 regarding refund mechanisms.

💡 Investors should monitor the final outcome of the writ petition as the stay is an interim relief against a significant potential liability. The news is positive in the short term as it removes immediate financial pressure on the company's balance sheet.

Morepen Laboratories Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Dec 2025, 01:29 PM

Morepen Laboratories Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the board meeting to approve unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially declared. This is a standard regulatory procedure for listed companies in India before earnings announcements.

Trading window closure effective from January 1, 2026
Closure pertains to the approval of financial results for the quarter and nine months ended December 31, 2025
Restriction applies to all designated persons and their immediate relatives
Window to reopen 48 hours after the announcement of the financial results

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's upcoming announcement regarding the date of the board meeting for Q3 results.

Morepen Labs Receives Show Cause Notice Regarding GST Refund Claim

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 04 Dec 2025, 12:36 PM

Morepen Laboratories has received a Show Cause Notice (SCN) from the GST Authority regarding a GST refund claim. The SCN alleges that the company erroneously claimed excess GST refund amounting to ₹117,94,03,452 under Section 54 of the CGST Act, 2017. The company had applied for refund of accumulated ITC on account of zero rated supply for the financial years 2020 to 2024. Morepen Labs contends that it claimed the refund as per GST Act provisions and will submit necessary information to the GST authority.

SCN received from GST Authority on December 3, 2025
Alleged excess GST refund claim of ₹117,94,03,452
SCN relates to financial years 2020-21, 2021-22, 2022-23 and 2023-24
Company applied for refund under Rule 89(4) instead of Rule 89(4B) of CGST Rules, 2017

💡 Investors should monitor the outcome of this legal matter and its potential financial implications. While the company believes the SCN has no merit, the final liability, if any, is yet to be ascertained.

MOREPENLAB: Report on Physical Share Transfer Requests - November 2025

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 01 Dec 2025, 04:54 PM

Morepen Laboratories Limited has submitted a report regarding the re-lodgement of physical share transfer requests for November 2025, as per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97. The report, received from MAS Services Limited, the Registrar and Transfer Agent, indicates that during the period of November 1, 2025, to November 30, 2025, there were NIL requests received, processed, approved or rejected. The average time taken for processing these requests was also 'NA'. This is a routine update related to compliance with SEBI regulations.

No. of requests received during the month: NIL
No. of requests processed during the month: NIL
No. of requests approved: NIL
No. of requests rejected: NIL

💡 This is a routine regulatory filing. Investors should monitor company announcements for any significant developments.

View All MOREPENLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company reported a marginal Total Operating Income (TOI) growth of 1.10% to INR 1,554.54 Cr in FY2025. Segment performance was mixed: Generics grew by 50% to INR 128.46 Cr, Institutional Supplies grew by 14.52% to INR 49.52 Cr, and Formulations grew by 3.90% to INR 138.69 Cr. API volumes increased 8.4% to 465 MT, but revenue was offset by an 8.1% decline in average realization from INR 21,886 to INR 20,111 per unit.

Geographic Revenue Split

Morepen exports to more than 80 countries, with recent growth driven by enhanced market penetration and customer acquisition in the European market. The company is also expanding its footprint through a Dubai-based subsidiary to target new international markets.

Profitability Margins

Profitability faced headwinds in FY2025; Operating Profit Margin declined from 10.52% to 9.87% and Net Profit Margin dropped from 7.16% to 6.47%. This compression was primarily due to escalating raw material costs in the API and home health segments and falling realizations in the API business.

EBITDA Margin

EBITDA margin stood at 9.87% in FY2025, a decrease of 65 basis points from 10.52% in FY2024. EBITDA absolute value fell 5.2% to INR 153.41 Cr from INR 161.82 Cr, reflecting the impact of intense pricing competition from Chinese manufacturers and higher input costs.

Capital Expenditure

The company raised INR 200 Cr through a Qualified Institutional Placement (QIP) to fund expansion. A significant portion is allocated to the high-growth medical devices segment, which is projected to contribute up to 45% of total revenue in the future. Actual QIP-related expenses were INR 10.92 Cr, lower than the projected INR 12.85 Cr.

Credit Rating & Borrowing

Infomerics assigned a long-term rating of 'IVR A-/Stable' in August 2025. The company maintains a low overall gearing of 0.09x and a Debt Equity Ratio of 0.07. Average fund-based working capital utilization is low at ~49%, indicating a strong liquidity buffer and low borrowing costs.

⚙️ Operational Drivers

Raw Materials

Key raw materials include API intermediates and components for home health devices (glucometers/BP monitors). Raw material costs are a critical component, and recent increases in these inputs led to negative inventory adjustments and margin pressure.

Import Sources

The company is exposed to volatility in both domestic and imported inputs. While specific countries are not listed for all inputs, the API segment faces significant competitive pressure and pricing dynamics influenced by Chinese manufacturers.

Key Suppliers

Not specifically disclosed in the available documents; however, the company is shifting away from low-margin third-party manufacturing to focus on in-house manufacturing capacities.

Capacity Expansion

API production capacity utilization is increasing, with production rising 10.7% from 448 MT in FY2024 to 496 MT in FY2025. The company is also expanding its medical device manufacturing complex in Baddi, which houses 10 specialized plants.

Raw Material Costs

Raw material costs increased in FY2025, particularly in the API and home health segments. While the company has mechanisms to pass on costs, a time lag in price adjustments typically exposes margins to interim pressure.

Manufacturing Efficiency

The company is focusing on better utilization of in-house manufacturing capacities to promote a stronger mix of high-margin trade and institutional sales.

Logistics & Distribution

The company distributes to over 80 countries and has a wide domestic reach for its 'Dr. Morepen' brand, which has sold over 12 million glucometers to date.

📈 Strategic Growth

Expected Growth Rate

9.30%

Growth Strategy

Growth will be achieved by scaling the medical devices segment to 45% of revenue, expanding the 'Dr. Morepen' consumer brand, and increasing direct institutional sales. The company is also investing in new-generation APIs (3.5-4 year development cycle) and expanding internationally via its Dubai subsidiary.

Products & Services

Active Pharmaceutical Ingredients (Montelukast, Loratadine), medical devices (glucometers, blood pressure monitors, thermometers), finished formulations, and the Dr. Morepen Sync App for health monitoring.

Brand Portfolio

Dr. Morepen, Morepen Rx.

New Products/Services

Launched the Dr. Morepen Sync App to monitor vital health metrics. New generation APIs are under development with a 3.5 to 4-year timeline to reach commercial production.

Market Expansion

Targeting the European market through enhanced customer acquisition and exploring new global territories via a Dubai-based subsidiary.

Market Share & Ranking

Global leadership in the production of Montelukast and Loratadine APIs. Over 12 million glucometers sold in India, indicating a leading position in the home health segment.

Strategic Alliances

The company realigned its business by transferring brand-sharing operations to its subsidiary, Dr. Morepen Limited, to streamline focus.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health (e.g., Sync App) and increased domestic manufacturing of medical devices. Morepen is positioning itself as an integrated player across APIs, devices, and formulations to capture this 10-15% sectoral growth.

Competitive Landscape

Faces intense competition from large-scale Chinese API manufacturers and domestic pharmaceutical players in the formulations and generics space.

Competitive Moat

Moat is built on a 40-year legacy, USFDA/WHO-GMP certified manufacturing, and the strong 'Dr. Morepen' brand equity in the Indian consumer healthcare market. Sustainability depends on successfully transitioning from legacy APIs to new-generation products.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and raw material price cycles. Profitability is highly correlated with the cost of API intermediates.

Consumer Behavior

Increasing proactive health management by consumers is driving demand for home-use medical devices like glucometers and BP monitors.

Geopolitical Risks

Trade dynamics with China significantly impact the API segment's pricing and margin profile.

⚖️ Regulatory & Governance

Industry Regulations

Highly regulated by USFDA, WHO-GMP, EU-GMP, TGA (Australia), and Anvisa (Brazil). Adherence to these international standards is mandatory for maintaining export market access.

Environmental Compliance

Operates under WHO-GMP and EU-GMP standards which require stringent environmental and quality controls at the Baddi manufacturing complex.

Taxation Policy Impact

The company is subject to standard Indian corporate tax rates; however, it is currently contesting a GST refund issue.

Legal Contingencies

Received a Show Cause Notice (SCN) on December 3, 2025, from the Central GST Commissionerate, Shimla, regarding an ITC refund claim for FY2020 to FY2024. The dispute involves the application of Rule 89(4) vs Rule 89(4B) of the CGST Rules.

⚠️ Risk Analysis

Key Uncertainties

Margin compression in the API segment (currently the largest revenue share) due to falling realizations and escalating costs remains the primary risk to earnings.